Stock Ratings / Health Care / ABEO / options

IMRX (45) AMRN (43) QTTB (61) BCYC (24) ⌘ Pro Terminal →

Abeona Therapeutics Inc. (ABEO) Options Positioning, Max Pain & Unusual Sweeps

$4.56 +0.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.55

Abeona Therapeutics Inc. (ABEO) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $260.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.55 (-0.15%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABEO)Realized 20D OHLCV Swing Band: ±9.9%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY ABEO SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (38% of score)

FRED Regime × Technicals: 15% of 52W Range • RSI-14 at 36.1 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (31% of score)

20D Institutional Volume Accumulation (±9.9% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$4.94-10.3% Next Q

Q2 (-2Q)

Grade D$4.43-0.7% Next Q

Q3 (-1Q)

Grade D$4.40+3.6% Next Q

Current

Grade D-$4.56-7.6% Hist 90D α

Trajectory: D (47) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ABEO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ABEO currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.24) and Max Pain ($4.79) forces dealer call-delta covering toward $8.03.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABEO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ABEO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±9.9%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ABEO)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ABEO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABEO)

✓Walkthrough of ABEO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ABEO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.48%📐 HORIZONTAL RANGE

2026-10-30O $4.50H $4.56L $4.31C $4.56VOL 783.0K

RES: $9.01SUP: $3.94SMA50: $5.24SMA200: $5.49

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABEO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABEO Butterfly Map → + Track ABEO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ABEO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABEO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ABEO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABEO)

Health Care Rank #673 of 1016 ⚔️ IMRX vs ABEO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABEO vs. IMRX, AMRN, QTTB, BCYC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Abeona Therapeutics Inc. (ABEO) ranks #673 by composite RQD confidence (39/100, grade D-) and #540 by equity capitalization ($260.8M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with ABEO at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ABEO ACTIVE Abeona Therapeutics Inc.	D-	39/100	—	73.7%	-35.0%	+0.22%	$260.8M	Benchmark Subject
IMRX Immuneering Corporation (Class A)	D	45/100	—	—	-35.0%	+0.75%	$260.1M	/imrx-vs-abeo →
AMRN Amarin Corporation plc	D-	43/100	—	56.6%	-12.2%	-0.08%	$262.8M	/amrn-vs-abeo →
QTTB Q32 Bio Inc.	C-	61/100	8.9x	—	85.0%	-2.10%	$264.1M	/qttb-vs-abeo →
BCYC Bicycle Therapeutics plc	E	24/100	—	—	-35.0%	-1.55%	$267.4M	/bcyc-vs-abeo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000318306

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Abeona Therapeutics Inc. (ABEO) reported GAAP revenue of $5.8M (N/A vs. FY2024 revenue of $0 , and +66.3% cumulative change since FY2023) , GAAP net income of -$71.2M, operating cash flow of -$76.3M, and free cash flow of -$84.3M (-44.2% YoY). On the balance sheet, ABEO closed FY2025 with $219.6M in total assets against $7.8M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$5.8M	-$71.2M	-$76.3M	-$84.3M	$219.6M	$7.8M
FY2024 (FY)	2024-12-31	$0	$63.7M	-$56.0M	-$58.5M	$108.9M	$13.0M
FY2023 (FY)	2023-12-31	$3.5M	$54.2M	-$37.0M	-$37.0M	—	—

3. ABEO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABEO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Abeona Therapeutics Inc. (NASDAQ: ABEO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $4.56 (+0.22% 1D, market cap $260.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABEO ranks #673 in composite RQD confidence.

How does ABEO compare to IMRX and AMRN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABEO carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 73.7%, and ROIC of -35.0%. By comparison, IMRX (Immuneering Corporation (Class A)) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $260.1M) and AMRN (Amarin Corporation plc) posts a D- grade (43/100 RQD, P/E N/A, ROIC -12.2%, cap $262.8M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ABEO?

Per ABEO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000318306), Abeona Therapeutics Inc. generated $5.8M in revenue, -$71.2M in net income, and -$84.3M in free cash flow against $219.6M in total assets and $7.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ABEO trading relative to its 50-day, 200-day, and 52-week technical levels?

ABEO last traded at $4.56 (+0.22% on volume of 874,347 shares), positioning the stock -12.98% below its 50-day simple moving average ($5.24) and -16.94% below its 200-day simple moving average ($5.49). Across its 52-week range of $4.00 to $7.65, ABEO sits at the 15.3% percentile with a 14-day RSI of 36.1 (NEUTRAL RANGE) and an implied next-earnings move of ±9.9% ($4.11 to $5.01).